Christine Stoops1, Sadie Stone2, Emily Evans2, Lynn Dill3, Traci Henderson2, Russell Griffin4, Stuart L Goldstein5, Carl Coghill6, David J Askenazi7. 1. Department of Pediatrics, University of Alabama at Birmingham; Department of Pediatrics, Children's of Alabama. Electronic address: christinestoops@uabmc.edu. 2. Department of Pediatrics, Children's of Alabama. 3. Department of Pediatrics, Children's of Alabama; The Pediatric and Infant Center for Acute Nephrology (PICAN). 4. Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL. 5. Department of Pediatrics, Cincinnati Children's Hospital Medical Center; Center for Acute Care Nephrology (CACN), Cincinnati, OH. 6. Department of Pediatrics, University of Alabama at Birmingham; Department of Pediatrics, Children's of Alabama. 7. Department of Pediatrics, University of Alabama at Birmingham; Department of Pediatrics, Children's of Alabama; The Pediatric and Infant Center for Acute Nephrology (PICAN).
Abstract
OBJECTIVE(S): To test if acute kidney injury (AKI) is preventable in patients in the neonatal intensive care unit and if infants at high-risk of nephrotoxic medication-induced AKI can be identified using a systematic surveillance program previously used in the pediatric non-intensive care unit setting. STUDY DESIGN: Quality improvement project that occurred between March 2015 and September 2017 in a single center, level IV neonatal intensive care unit. Infants were screened for high-risk nephrotoxic medication exposure (≥3 nephrotoxic medication within 24 hours or ≥4 calendar days of an intravenous [IV] aminoglycoside). If infants met criteria, a daily serum creatinine (SCr) was obtained until 2 days after end of exposure or end of AKI, whichever occurred last. The study was divided into 3 eras: pre-Nephrotoxic Injury Negated by Just-in-time Action (NINJA), initiation, and sustainability. Differences for 5 metrics across 3 eras were compared: SCr surveillance, high nephrotoxic medication exposure rate (per 1000 patient-days), AKI rate (per 1000 patient-days), nephrotoxin-AKI percentage, and AKI intensity (number of AKI days per 100 susceptible patient-days). RESULTS: Comparing the initiation with sustainability era, there was a reduction in high nephrotoxic medication exposures from 16.4 to 9.6 per 1000 patient-days (P = .03), reduction in percentage of nephrotoxic medication-AKI from 30.9% to 11.0% (P < .001), and reduction in AKI intensity from 9.1 to 2.9 per 100 susceptible patient-days (P < .001) while maintaining a high SCr surveillance rate. This prevented 100 AKI episodes during the 18-month sustainability era. CONCLUSION(S): A systematic surveillance program to identify high-risk infants can prevent nephrotoxic-induced AKI and has the potential to prevent short and long-term consequences of AKI in critically ill infants.
OBJECTIVE(S): To test if acute kidney injury (AKI) is preventable in patients in the neonatal intensive care unit and if infants at high-risk of nephrotoxic medication-induced AKI can be identified using a systematic surveillance program previously used in the pediatric non-intensive care unit setting. STUDY DESIGN: Quality improvement project that occurred between March 2015 and September 2017 in a single center, level IV neonatal intensive care unit. Infants were screened for high-risk nephrotoxic medication exposure (≥3 nephrotoxic medication within 24 hours or ≥4 calendar days of an intravenous [IV] aminoglycoside). If infants met criteria, a daily serum creatinine (SCr) was obtained until 2 days after end of exposure or end of AKI, whichever occurred last. The study was divided into 3 eras: pre-Nephrotoxic Injury Negated by Just-in-time Action (NINJA), initiation, and sustainability. Differences for 5 metrics across 3 eras were compared: SCr surveillance, high nephrotoxic medication exposure rate (per 1000 patient-days), AKI rate (per 1000 patient-days), nephrotoxin-AKI percentage, and AKI intensity (number of AKI days per 100 susceptible patient-days). RESULTS: Comparing the initiation with sustainability era, there was a reduction in high nephrotoxic medication exposures from 16.4 to 9.6 per 1000 patient-days (P = .03), reduction in percentage of nephrotoxic medication-AKI from 30.9% to 11.0% (P < .001), and reduction in AKI intensity from 9.1 to 2.9 per 100 susceptible patient-days (P < .001) while maintaining a high SCr surveillance rate. This prevented 100 AKI episodes during the 18-month sustainability era. CONCLUSION(S): A systematic surveillance program to identify high-risk infants can prevent nephrotoxic-induced AKI and has the potential to prevent short and long-term consequences of AKI in critically ill infants.
Authors: F Perry Wilson; Michael Shashaty; Jeffrey Testani; Iram Aqeel; Yuliya Borovskiy; Susan S Ellenberg; Harold I Feldman; Hilda Fernandez; Yevgeniy Gitelman; Jennie Lin; Dan Negoianu; Chirag R Parikh; Peter P Reese; Richard Urbani; Barry Fuchs Journal: Lancet Date: 2015-02-26 Impact factor: 79.321
Authors: Sehoon Park; Seon Ha Baek; Soyeon Ahn; Kee-Hyuk Lee; Hee Hwang; Jiwon Ryu; Shin Young Ahn; Ho Jun Chin; Ki Young Na; Dong-Wan Chae; Sejoong Kim Journal: Am J Kidney Dis Date: 2017-07-25 Impact factor: 8.860
Authors: Stuart L Goldstein; Eric Kirkendall; Hovi Nguyen; Joshua K Schaffzin; John Bucuvalas; Tracey Bracke; Michael Seid; Marshall Ashby; Natalie Foertmeyer; Lori Brunner; Anne Lesko; Cynthia Barclay; Carole Lannon; Stephen Muething Journal: Pediatrics Date: 2013-08-12 Impact factor: 7.124
Authors: Jennifer G Jetton; Louis J Boohaker; Sidharth K Sethi; Sanjay Wazir; Smriti Rohatgi; Danielle E Soranno; Aftab S Chishti; Robert Woroniecki; Cherry Mammen; Jonathan R Swanson; Shanty Sridhar; Craig S Wong; Juan C Kupferman; Russell L Griffin; David J Askenazi Journal: Lancet Child Adolesc Health Date: 2017-11
Authors: Ana Flávia Lima Ruas; Gabriel Malheiros Lébeis; Nicholas Bianco de Castro; Vitória Andrade Palmeira; Larissa Braga Costa; Katharina Lanza; Ana Cristina Simões E Silva Journal: Pediatr Nephrol Date: 2021-11-30 Impact factor: 3.651
Authors: Hailey W Gavigan; Cara L Slagle; Kelli A Krallman; Brenda B Poindexter; David K Hooper; Stuart L Goldstein Journal: Pediatr Nephrol Date: 2021-01-22 Impact factor: 3.714